Antibody drug conjugates comprising sting agonists

Patent metadata

Field	Value
Publication number	US-12440576-B2
Application number	US-202218068476-A
Country	US
Kind code	B2
Filing date	Dec 19, 2022
Priority date	Apr 2, 2020
Publication date	Oct 14, 2025
Grant date	Oct 14, 2025

Abstract

The present disclosure provides scaffolds and antibody-drug conjugates (ADCs) comprising a stimulator of interferon genes (STING). The present disclosure also provides uses of the ADCs in treatment, e.g., treatment of cancer.

First claim

What is claimed is:

1. An antibody-drug conjugate (ADC) being

or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein the HER2 antibody comprises a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence FTFSSYSMN (SEQ ID NO: 20); a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence YISSSSSTIYYADSVKG (SEQ ID NO: 21); a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GGHGYFDL (SEQ ID NO: 22); a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence RASQSVSSSYLA (SEQ ID NO: 27); a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GASSRAT (SEQ ID NO: 28); and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYHHSPLT (SEQ ID NO: 29), and d 15 represents an integer ranging from about 1 to about 20.

2. The conjugate of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the HER2 antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 17 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 24.

3. The conjugate of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the HER2 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 19 and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 26.

4. The conjugate of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein d 15 represents an integer ranging from about 2 to about 14.

5. The conjugate of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein d 15 represents an integer ranging from about 2 to about 8.

6. The conjugate of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein d 15 is about 2, about 4, about 6, or about 8.

7. The conjugate of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein d 15 is an integer ranging from about 6 to about 10.

8. The conjugate of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein d 15 is about 6.

9. The conjugate of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein d 15 is about 7.

10. The conjugate of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, wherein d 15 is about 8.

11. A pharmaceutical composition comprising the conjugate of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof, and one or more pharmaceutically acceptable carriers or excipients.

12. The pharmaceutical composition of claim 11 , further comprising at least one immuno-modulator or at least one immunostimulatory agent.

13. A method of activating or enhancing an activity of a stimulator of interferon genes (STING) in a subject, comprising administering to the subject the conjugate of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.

14. A method of treating a disease or disorder associated with the modulation of STING in a subject, comprising administering to the subject the conjugate of claim 1 , or a pharmaceutically acceptable salt or stereoisomer thereof.

15. The method of claim 14 , wherein the disease or disorder is cancer.

16. The method of claim 15 , wherein the cancer is bladder cancer, breast cancer, colorectal cancer, colon cancer, endometrial cancer, gastric cancer, head and neck squamous carcinoma, melanoma, lung cancer, ovarian cancer, esophageal cancer, biliary cancer, urothelial cancer, cervical cancer, papillary thyroid cancer, papillary renal cell cancer, cholangiocarcinoma, salivary duct cancer, kidney cancer, or pancreatic cancer.

17. The method of claim 16 , wherein the cancer is breast cancer, colorectal cancer, gastric cancer, or lung cancer.

18. An antibody-drug conjugate (ADC) being

or a pharmaceutically acceptable salt or stereoisomer thereof,
wherein the HER2 antibody comprises a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence FTFSSYSMN (SEQ ID NO: 20); a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence YISSSSSTIYYADSVKG (SEQ ID NO: 21); a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GGHGYFDL (SEQ ID NO: 22); a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence RASQSVSSSYLA (SEQ ID NO: 27); a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GASSRAT (SEQ ID NO: 28); and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYHHSPLT (SEQ ID NO: 29), and d 15 represents an integer ranging from about 1 to about 20.

19. An antibody-drug conjugate of Formula (I):
PBRM-[A 1 -(L C )-D] d15   (I),

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:
A 1 is

wherein * denotes attachment to PBRM and ** denotes attachment to L C ;
L C is

wherein # denotes attachment to A 1 and ## denotes attachment to D;
M A is

wherein * denotes attachment to A 1 , ** denotes attachment to T 1 , and *** denotes attachment to L D ;
L D is ***—NH—(CH 2 CH 2 O) 2 —(CH 2 ) 2 —C(O)-(alanine)-****, wherein* denotes attachment to M A and **** denotes attachment to D;
T 1 is

wherein n 4 is 8;
D is

wherein R 2 is —O—, and

denotes attachment to L D ;
PBRM is a HER2 antibody comprising a variable heavy chain complementarity determining region 1 (CDRH1) comprising the amino acid sequence FTFSSYSMN (SEQ ID NO: 20); a variable heavy chain complementarity determining region 2 (CDRH2) comprising the amino acid sequence YISSSSSTIYYADSVKG (SEQ ID NO: 21); a variable heavy chain complementarity determining region 3 (CDRH3) comprising the amino acid sequence GGHGYFDL (SEQ ID NO: 22); a variable light chain complementarity determining region 1 (CDRL1) comprising the amino acid sequence RASQSVSSSYLA (SEQ ID NO: 27); a variable light chain complementarity determining region 2 (CDRL2) comprising the amino acid sequence GASSRAT (SEQ ID NO: 28); and a variable light chain complementarity determining region 3 (CDRL3) comprising the amino acid sequence QQYHHSPLT (SEQ ID NO: 29); and
d 15 represents an integer ranging from about 1 to about 20.

20. The conjugate of claim 19 , or a pharmaceutically acceptable sal

Assignees

• Mersana Therapeutics Inc

Inventors

• Duvall Jeremy R
• Bentley Keith W
• Bukhalid Raghida A
• Cetinbas Naniye
• Damelin Marc I
• Kelleher Eugene W
• Lowinger Timothy B
• Thomas Joshua D
• Toader Dorin
• Xu Ling
• Yang Liping

Classifications

• C07K16/11

  Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV] · CPC title

• A61K47/6803 Primary

  Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/437

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• A61K31/428

  condensed with carbocyclic rings · CPC title